• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    ccr-22-1268.pdf
    Size:
    1.649Mb
    Format:
    PDF
    Description:
    Identified with Open Access button
    Download
    Authors
    Banerjee, S.
    Michalarea, V.
    Ang, J. E.
    Ingles Garces, A.
    Biondo, A.
    Funingana, I. G.
    Little, Martin
    Ruddle, R.
    Raynaud, F.
    Riisnaes, R.
    Gurel, B.
    Chua, S.
    Tunariu, N.
    Porter, J. C.
    Prout, T.
    Parmar, M.
    Zachariou, A.
    Turner, A.
    Jenkins, B.
    McIntosh, S.
    Ainscow, E.
    Minchom, A.
    Lopez, J.
    de Bono, J.
    Jones, R.
    Hall, E.
    Cook, Natalie
    Basu, B.
    Banerji, U.
    Show allShow less
    Affiliation
    Royal Marsden NHS Foundation Trust, London, London, United Kingdom
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Purpose CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR-overexpressing tumours. Patients and methods: A 3+3 dose escalation design was used. During dose escalation, CT900 doses of 1-6 mg/m2 weekly and 2-12 mg/m2 every 2 weeks (q2Wk) intravenously were evaluated. Patients with high-grade serous ovarian cancer (HGSOC) were enrolled in the expansion cohorts. Results: 109 patients were enrolled, 42 patients in the dose escalation and 67 patients in the expansion cohorts. At the dose/schedule of 12 mg/m2/q2Wk (with and without dexamethasone, n=40), the most common treatment related adverse events were fatigue, nausea, diarrhoea, cough, anaemia and pneumonitis, which were predominantly grade 1 and grade 2. Levels of CT900 greater than 600 nM needed for growth inhibition in preclinical models were achieved for >65 hours at a dose of 12 mg/m2. In the expansion cohorts, the overall response rate (ORR), was 14/64 (21·9%). Thirty-eight response-evaluable patients in the expansion cohorts receiving 12 mg/m2/q2Wk had tumour evaluable for quantification of α-FR. Patients with high or medium expression had an objective response rate of 9/25 (36%) compared with 1/13 (7·7%) in patients with negative/very low or low expression of α‑FR. Conclusions: The dose of 12 mg/m2/q2Wk was declared the recommended phase II dose/schedule. At this dose/schedule, CT900 exhibited an acceptable side effect profile with clinical benefit in patients with high/medium α‑FR expression and warrants further investigation.
    Citation
    Banerjee S, Michalarea V, Ang JE, Ingles Garces A, Biondo A, Funingana IG, et al. A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Aug 19. PubMed PMID: 35984704. Epub 2022/08/20. eng.
    Journal
    Clinical Cancer Research
    URI
    http://hdl.handle.net/10541/625577
    DOI
    10.1158/1078-0432.ccr-22-1268
    PubMed ID
    35984704
    Additional Links
    https://dx.doi.org/10.1158/1078-0432.ccr-22-1268
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1158/1078-0432.ccr-22-1268
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.